Hoffmann-La-Roche process

The C5 aldehyde intermediate is produced from butadiene via catalytic oxidative acetoxylation followed by rhodium-catalyzed hydroformylation (see Fig. 2.30). Two variations on this theme have been described. In the Hoffmann-La-Roche process a mixture of butadiene, acetic acid and air is passed over a palladium/tellurium catalyst. The product is a mixture of cis- and frans-l,4-diacetoxy-2-butene. The latter is then subjected to hydroformylation with a conventional catalyst, RhH(CO)(Ph3P)3, that has been pretreated with sodium borohydride. When the aldehyde product is heated with a catalytic amount of p-toluenesulphonic acid, acetic acid is eliminated to form an unsaturated aldehyde. Treatment with a palladium-on-charcoal catalyst causes the double bond to isomerize, forming the desired Cs-aldehyde intermediate. 

Hoffmann-La Roche Process for the Manufacture of alpha-iA-Me-thyl-Phenyl)-13-Methyl-Amino-Propan 1943 GB 552,076... 

The discovery that calcitriol is actually the active vitamin / hormone, has reinvigorated Vitamin D research, and has initiated numerous efforts to prepare this compound. [93, 94] Hoffmann-La Roches process for manufacturing calcitriol in commercial quantities [95] follows conceptually a synthesis method of Sir Derek H. R. Barton (1918-1998) and Robert H. Hesse. [96]... 

II, factor X, coenzyme R, anti-egg white injury, vitamin Bg, or vitamin H, was established in 1942 and its synthesis was achieved a year later (1). The absolute configuration of biotin was elucidated by x-ray crystallographic analysis on biotin and on a TVi-carboxy derivative (reviewed in 2). NMR studies (3,4) demonstrated that the conformation of the thiophene ring is the same in the solid state and in solution the sulfur atom lies above the thiophene ring and the valeric chain adopts a quasi-equatorial position (Fig. 1). The same conformation is encountered in the biotin sulfoxides (Fig. 2) (3,4). Numerous total syntheses of biotin have been published and this topic has been thoroughly reviewed recently (5), but the bulk of biotin is still produced according to the original Hoffmann-La Roche process (5). 

Significant producers include Daiichi, Hoffmann-La Roche, Takeda, and several factories in mainland China. Takeda and Daiichi practice processes based on alanine by ethoxyoxazole (12), at least one Chinese producer from alanine by oxazole acid (13), and Roche from ketene via cyanooxazole (15). 

Vitamin A acetate [11098-51-4] (2) is the commercially significant form of the vitamin and is mainly produced by Hoffmann-La Roche, BASF, and Rhc ne-Poulenc (Fig. 4). AH of these processes have P ionone (18) as their key intermediate and in this regard are based on work performed in the 1940s... 

In a novel approach to vitamin K, Hoffmann-La Roche has exploited the potential acidity at C-3 as a means to attach the side chain of vitamin (36). Menadione was reacted with cyclopentadiene to yield the Diels-Alder adduct. The adduct is treated with base and alkylated at C-3 with phytyl chloride. A retro Diels-Alder reaction yields vitamin K. Process improvements in this basic methodology have been claimed by Japanese workers (37). 

WO 2006/111491 Al, F Hoffmann-La Roche AG Process forthe preparation of9,10-Dehydro-12.13-Desoxyepothilone Derivatives R1645 KOS1584 Phase II material has been manufactured, http //www.roche.com/home/media/med div/med div pharma/med pha 2007/... 

In a process developed by Hoffmann La Roche (Roessler, 1996) for the anti-Parkinsonian drug, lazabemide, palladium-catalysed amidocarbonylation of 2,5-dichloropyridine replaced an original synthesis that involved eight steps, starting from 2-methyl-5-ethylpyridine, and had an overall yield of 8%. The amidocarbonylation route affords lazabemide hydrochloride in 65% yield in one step, with 100% atom efficiency (Fig. 2.22). 

Taq polymerase is useful in the polymerase chain reaction (PCR) and the European patent rights for the PCR process and Taq polymerase were sold by Cetus in the early 1990 s to Hoffmann La Roche for approximately 300 milhonUS dollars. 

Yves Roggo, F. Hoffmann-La Roche, Ltd., Basel, Switzerland, Process Analytical Technology Chemical Imaging and Chemometrics Useful Tools for Process Analytical Technology... 

In 1988, an improved synthesis of orlistat (1) was reported by the Hoffmann-La Roche discovery chemistry. The scheme involved a pivotal P-lactone 14. In the approach, an aldol condensation of aldehyde 7 with the dianion generated from octanoic acid and two equivalents of LDA. After tosylic acid-facilitated lactonization and Jones oxidation, the resultant lactone 14/14 was hydrogenated to establish two additional chiral centers. A battery of somewhat tedious protections and deprotections transformed 15 to P-lactone 19 via the intermediacy of 16,17, and 18. Six additional steps then converted P-lactone 19 to orlistat (1). This route may provide better overall yield in comparison to the previous scheme. However, too many protections and deprotections render this approach less elegant and not very practical for large-scale process. 

Kaiy Mullis and others at Cetus Corporation in Berkeley, California, invented a technique for multiplying DNA sequences in vitro by, the polymerase chain reaction (PCR). PCR has been called the most revolutionary new technique in molecular biology in the 1980s. Cetus patented the process, and in the summer of 1991 sold the patent to Hoffmann La Roche. Inc. for 300 million. 

The best results were obtained in an indirect process 12S) developed by Hoffmann-La Roche, in which Fremy s salt was produced eleetrochemically ... 

We gratefully acknowledge the contributions to this work of Dr. John F. Blount and Mr. Louis Todaro (X-ray results and ORTEP figures), Dr. Arnold B. Davidson and Mr. Edward Boff results), and Dr. Robert O Brien and Mr. Go binding results), and Drs. David Coffen and Urs Hengartner (process research) all of Hoffmann-La Roche, Nutley. We especially thank Drs. K. Nakamura and I. Kuruma (JH-Ro 22-1319 binding results) of the Nippon Roche Research Center, Kamakura. 

The route described by Hoffmann-La Roche scientists in 1995 was designed to make use of the drug substance 5-DFCR (10) to prepare capecitabine in a few steps without multiple protection/deprotection transformations.19 In this process, 5 -deoxy-5-fluorocytodine (10)24 27 was added to three equivalents of -pentyl chloroformate and pyridine in methylene chloride while maintaining an internal temperature below -5 °C, ultimately providing the tris-acylated cytodine adduct 26 in a 92% isolated yield. Removal of the two ester functional groups by selective hydrolysis with aqueous sodium hydroxide in methanol at -10 °C for a short time followed by adjustment to pH5 with concentrated HCI provided the crude carbamate 1 in quantitative yield. Purification of... 

New synthetic processes for the preparation of established products were also industrially developed in Japan the manufacture of methyl methacrylate from C4 olefins, by Sumitomo and Nippon Shokubai in France, the simultaneous production of hydroquinone and pyro-catechin through hydrogen peroxide oxidation of phenol by Rhone-Poulenc in the United States the production of propylene oxide through direct oxidation of propylene operating jointly with styrene production, developed by Ralph Landau and used in the Oxirane subsidiary with Arco, which the latter fully took over in 1980 in Germany and Switzerland, the synthesis of vitamin A from terpenes, used by BASF and Hoffmann-La Roche. 

The authors are very grateful to J. Harwalik, Fachhochschule Furtwangen for the contribution of process automation, and to T Kircher, Fachhochschule Aalen and L. Devetta, Universita di Padova for their contribution in applying this system for kinetic studies. As well, many thanks to all the members of VFH at F. Hoffmann La-Roche AG for their invaluable help, namely R. Bemauer, B. Kem, H. Kleisner, Dr. F. Roessler, P. Rindisbacher and R. Zimmer. 

In the process practiced by Hoffmann-La Roche, a 0 3 + + Cg strategy is employed. In this approach, p-ionone (18) is subjected to a Dar2en s... 

The electrochemical process initially was developed by N. Ibl and coworkers at ETH, Zurich it was technically applied for several years by Hoffmann La-Roche [109], and it is said that Merck is using the reaction in the industrial production of Vitamin C [91]. Hoffmann La-Roche used the Swiss-roH cell as electrolyzer (Fig. 19). Three-dimensional electrodes are discussed in Refs. 110 and 111. 

Structure 4 is an intermediate for manufaeturing vitamin A (Scheme 2). The annual demand for vitamin A is about 3000 tons. Major producers are BASF, Hoffmann-La Roche and Rhone-Poulenc Animal Nutrition [55]. At an early stage in the synthesis BASF and Hoffmann-La Roche are using a hydroformylation step to synthesize 4 starting from l,2-diacetoxy-3-butene (5) and 1,4-di-aeetoxy-2-butene (6), respectively [56, 57]. The selectivity toward the branched product in the BASF process is achieved by using an unmodified rhodium carbonyl catalyst at a high reaction temperature. The symmetry of 6 in La Roche s process does not lead to regioselectivity problems. Elimination of acetic acid and isomerization of the exo double bond (La Roche) yields the final product 4 in both processes. 

The glyoxylate-ene reaction, promoted by the Ti-BINOL complex, produces chiral a-hydroxy esters, which provide an easy access to the corresponding carboxylic acid derivatives bearing a chiral center at the a position. The adduct between the glyoxylate and exo olefin is proposed as a key intermediate of the collagenase-selective inhibitor, Trocade (Hoffmann-La Roche) [20]. This remarkable process has been developed for large-scale production. 

---